Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.
Pharmacologic blockade of EGFR or the closely related receptor ERBB2 has modest efficacy against colorectal cancers in the clinic. Although the upregulation of ERBB3, a pseudo-kinase member of the EGFR/ERBB family, is known to contribute to EGFR inhibitor resistance in other cancers, its functions in normal and malignant intestinal epithelium have not been defined. We have shown here that the intestinal epithelium of mice with intestine-specific genetic ablation of Erbb3 exhibits no cytological abnormalities but does exhibit loss of expression of ERBB4 and sensitivity to intestinal damage. By contrast, intestine-specific Erbb3 ablation resulted in almost complete absence of intestinal tumors in the ApcMin mouse model of colon cancer. Unlike nontransformed epithelium lacking ERBB3, intestinal tumors lacking ERBB3 had reduced PI3K/AKT signaling, which led to attenuation of tumorigenesis via a tumor-specific increase in caspase-3-mediated apoptosis. Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis. These results indicate that the ERBB3 pseudo-kinase has essential roles in supporting intestinal tumorigenesis and suggest that ERBB3 may be a promising target for the treatment of colorectal cancers.
Lee
Daekee
D
Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA. daekee@ewha.ac.kr
Yu
Ming
M
Lee
Eunjung
E
Kim
Hyunok
H
Yang
Yanan
Y
Kim
Kyoungmi
K
Pannicia
Christina
C
Kurie
Jonathan M
JM
Threadgill
David W
DW
D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000502:physiology*; D001483:Base Sequence; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005260:Female; D017491:Genes, APC; D018815:Genes, erbB; D006801:Humans; D007413:Intestinal Mucosa / Q000201:enzymology* / Q000473:pathology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008954:Models, Biological; D034741:RNA, Small Interfering / Q000235:genetics; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000172:deficiency* / Q000235:genetics; D066247:Receptor, ErbB-4
D034741:RNA, Small Interfering; C587689:ERBB4 protein, human; D066246:ErbB Receptors; C587690:Erbb4 protein, mouse; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C505409:Casp3 protein, mouse; D053148:Caspase 3
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10416-20
1720540
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6
8058768
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6
1715580
Cancer Res. 2006 Jan 1;66(1):192-7
16397232
Nature. 1997 Oct 16;389(6652):725-30
9338783
Mamm Genome. 2004 Jul;15(7):525-36
15366372
Science. 2007 May 18;316(5827):1039-43
17463250
Development. 1997 Dec;124(24):4999-5011
9362461
Clin Mol Pathol. 1996 Aug;49(4):M199-202
16696074
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6
11818567
J Clin Oncol. 2005 Dec 20;23(36):9265-74
16361624
J Biol Chem. 1994 Oct 7;269(40):24747-55
7929151
Nat Rev Cancer. 2005 May;5(5):341-54
15864276
Nature. 2003 Feb 27;421(6926):942-7
12607001
Biochem J. 1998 Aug 1;333 ( Pt 3):757-63
9677338
World J Gastroenterol. 2007 Nov 28;13(44):5877-87
17990353
Clin Lung Cancer. 2004 Dec;6 Suppl 1:S7-S19
15638959
Biochem J. 1997 Mar 15;322 ( Pt 3):757-63
9148746
Oncogene. 2004 Jul 29;23(34):5781-91
15208671
Cancer Res. 2007 Jun 1;67(11):5389-96
17545620
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
16341064
Science. 2002 May 31;296(5573):1655-7
12040186
Mech Dev. 2002 Dec;119 Suppl 1:S97-S101
14516668
Trends Cell Biol. 2006 Sep;16(9):443-52
16879967
Genome Biol. 2007;8(7):R131
17615082
Mol Cell Biol. 2004 Oct;24(20):8907-16
15456865
Eur J Gastroenterol Hepatol. 2001 Jul;13(7):763-70
11474304
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
12853564
Br J Cancer. 1998 Nov;78(10):1385-90
9823984
J Biol Chem. 2002 Sep 6;277(36):33275-83
12065599
J Gastrointest Surg. 2004 Mar-Apr;8(3):274-6
15019922
Mol Cell Biol. 1994 Jun;14(6):3550-8
7515147
J Biol Chem. 2004 Oct 8;279(41):43261-72
15294912
Hum Pathol. 1998 Aug;29(8):771-7
9712416
Ann N Y Acad Sci. 1999 Jun 30;880:110-21
10415856
Oncogene. 2003 Mar 6;22(9):1294-301
12618754
Cancer Res. 2006 Aug 1;66(15):7708-15
16885373
EMBO J. 1994 Jun 15;13(12):2831-41
8026468
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
15731348
Cancer Res. 2003 Aug 1;63(15):4368-74
12907606
EMBO J. 1999 Apr 15;18(8):2149-64
10205169